Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial - PubMed
6 hours ago
- #clinical-trial
- #bimagrumab-semaglutide
- #obesity-treatment
- Bimagrumab and semaglutide were tested alone and in combination for obesity treatment in a phase 2 trial.
- 507 adults with obesity (BMI ≥30 or ≥27 with complications) were randomized into nine treatment groups.
- Treatments included placebo, bimagrumab (10 mg/kg or 30 mg/kg IV every 12 weeks), semaglutide (1.0 mg or 2.4 mg SC weekly), and combinations.
- Primary endpoint: absolute change in body weight at week 48; secondary endpoint: week 72.
- High-dose combination (bimagrumab 30 mg/kg + semaglutide 2.4 mg) showed the highest weight loss (-17.8 kg vs. placebo -3.3 kg).
- Adverse effects for bimagrumab included muscle spasms, diarrhea, and acne; semaglutide caused nausea, diarrhea, constipation, and fatigue.
- Safety profiles were consistent with known drug effects, and weight loss improvements continued through week 72.
- Trial registered as NCT05616013, with conflicts of interest disclosed among authors and sponsors (Eli Lilly and Company).